Key execs recruited to boost Eisai's Alzheimer's team

In its pursuit to address the entire scope of Alzheimer's disease (AD), Japanese pharma major Eisai’s (TYO: 4523) US subsidiary is expanding its AD business with the immediate appointments of two renowned experts in the neuroscience field.

Dr Harald Hampel joins the company as vice president, global medical affairs. Dr Michael Irizarry has been named VP, clinical research. Both executives will work on advancing the company's extensive pipeline of Alzheimer's disease and dementia compounds.

Dr Hampel most recently served as full Professor and Excellence Chair, Scientific Director at the Institute for Memory and Alzheimer's Disease, European Center of Excellence in Neurodegenerative Disease at Sorbonne University in Paris, France.